The Norwegian tenecteplase stroke trial (NOR-TEST): randomised controlled trial of tenecteplase vs. alteplase in acute ischaemic stroke
Logallo, Nicola; Kvistad, Christopher Elnan; Nacu, Aliona; Næss, Halvor; Waje-Andreassen, Ulrike; Asmuss, Jörg; Aamodt, Anne Hege; Lund, Christian; Kurz, Martin; Rønning, Ole Morten; Salvesen, Rolf; Idicula, Titto T.; Thomassen, Lars
Peer reviewed, Journal article
Published version
![Thumbnail](/bora-xmlui/bitstream/handle/1956/8670/1471-2377-14-106.pdf.jpg?sequence=8&isAllowed=y)
Date
2014-05-15Metadata
Show full item recordCollections
Original version
https://doi.org/10.1186/1471-2377-14-106Abstract
Background: Alteplase is the only approved thrombolytic agent for acute ischaemic stroke. The overall benefit from alteplase is substantial, but some evidence indicates that alteplase also has negative effects on the ischaemic brain. Tenecteplase may be more effective and less harmfull than alteplase, but large randomised controlled phase 3 trials are lacking. The Norwegian Tenecteplase Stroke Trial (NOR-TEST) aims to compare efficacy and safety of tenecteplase vs. alteplase. Methods/Design: NOR-TEST is a multi-centre PROBE (prospective randomised, open-label, blinded endpoint) trial designed to establish superiority of tenecteplase 0.4 mg/kg (single bolus) as compared with alteplase 0.9 mg/kg (10% bolus + 90% infusion/60 minutes) for consecutively admitted patients with acute ischaemic stroke eligible for thrombolytic therapy, i.e. patients a) admitted <4½ hours after symptoms onset; b) admitted <4½ hours after awakening with stroke symptoms c) receiving bridging therapy before embolectomy. Randomisation tenecteplase:alteplase is 1:1. The primary study endpoint is favourable functional outcome defined as modified Rankin Scale 0–1 at 90 days. Secondary study endpoints are: 1) haemorrhagic transformation (haemorrhagic infarct/haematoma); 2) symptomatic cerebral haemorrhage on CT 24–48 hours; 3) major neurological improvement at 24 hours; 4) recanalisation at 24–36 hours; 5) death. Discussion: NOR-TEST may establish a novel approach to acute ischaemic stroke treatment. A positive result will lead to a more effective, safer and easier treatment for all acute ischaemic stroke pasients. NOR-TEST is reviewed and approved by the Regional Committee for Medical and Health Research Ethics (2011/2435), and The Norwegian Medicines Agency (12/01402). NOR-TEST is registered with EudraCT No 2011-005793-33 and in ClinicalTrials.gov (NCT01949948).
Publisher
BioMed CentralJournal
BMC NeurologyCopyright
Nicola Logallo et al.; licensee BioMed Central Ltd.Copyright 2014 Logallo et al.; licensee BioMed Central Ltd